search
Back to results

Screening for Renal Complications in Children and Young Adults With Major Sickle Cell Disease (NEPHRO-DREPA)

Primary Purpose

Anemia, Sickle Cell Disease

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Kidney function assessment
Sponsored by
Centre Hospitalier Universitaire de Nice
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Anemia focused on measuring Sickle cell disease, Renal complication

Eligibility Criteria

1 Year - 21 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

- Patient over 1 year old followed up in the Competence Centre at the Nice University Hospital, treated for a major sickle cell disease during the annual check-up

Exclusion Criteria:

  • Pregnant patients (positive urine pregnancy test)
  • Patients with other chronic conditions
  • Progressive cancer or kidney disease
  • Patients who are breastfeeding

Sites / Locations

  • CHU de NiceRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Kidney function assessment

Arm Description

Outcomes

Primary Outcome Measures

renal clearance
renal clearance measured by scintigraphy

Secondary Outcome Measures

Full Information

First Posted
January 6, 2022
Last Updated
July 19, 2023
Sponsor
Centre Hospitalier Universitaire de Nice
search

1. Study Identification

Unique Protocol Identification Number
NCT05211037
Brief Title
Screening for Renal Complications in Children and Young Adults With Major Sickle Cell Disease
Acronym
NEPHRO-DREPA
Official Title
Screening for Renal Complications in Children and Young Adults With Major Sickle Cell Disease
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 15, 2022 (Actual)
Primary Completion Date
September 2024 (Anticipated)
Study Completion Date
September 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Nice

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Sickle cell disease is the subject of targeted neonatal screening (carried out when one of the two parents is from an endemic country - sub-Saharan Africa, South-East Asia, Central America, the Caribbean) during the Guthrie test. Haemolysis, which results from the abnormality of the haemoglobin, and the vascular activation it causes, are responsible for multiple organ damage. Major sickle cell syndromes (MSC), by several mechanisms, are responsible for a wide range of renal damage, culminating in end-stage renal failure at an average age of 45 years and with an average survival of 3 years beyond ESRD. The various renal disorders are : glomerular hyperfiltration and then glomerulosclerosis; tubular dysfunction, especially proximal and distal hyposthenuria (a factor in enuresis); papillary necrosis, renal infarction, episodes of acute renal failure during vaso-occlusive crises; dysregulation of the renin-angiotensin system with early arterial hypertension and, more rarely, extra-membranous glomerulonephritis. In the early stages of these conditions, simple paraclinical tests can identify them before the appearance of specific clinical signs. In patients suffering from MDS, the HAS (High Authority of Health) recommends an annual check-up carried out in a Competence Centre. According to the HAS recommendations for annual surveillance, in addition to the search for other organic complications, for renal pathology, only microalbuminuria and renal ultrasound are recommended. However, as the literature shows, microalbuminuria and ultrasound only detect some of these renal disorders and at a very late stage. A large number of publications in adults and, to a lesser degree, in children, demonstrate the correlation between the frequency of acute complications of sickle cell disease (episodes of haemolysis, etc.) and the occurrence of kidney damage.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anemia, Sickle Cell Disease
Keywords
Sickle cell disease, Renal complication

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Kidney function assessment
Arm Type
Experimental
Intervention Type
Diagnostic Test
Intervention Name(s)
Kidney function assessment
Intervention Description
kidney clearance measured by scintigraphy
Primary Outcome Measure Information:
Title
renal clearance
Description
renal clearance measured by scintigraphy
Time Frame
at baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - Patient over 1 year old followed up in the Competence Centre at the Nice University Hospital, treated for a major sickle cell disease during the annual check-up Exclusion Criteria: Pregnant patients (positive urine pregnancy test) Patients with other chronic conditions Progressive cancer or kidney disease Patients who are breastfeeding
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Camille FAUDEUX, Dr
Phone
4.92.03.63.65
Ext
+33
Email
faudeux.c@chu-nice.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Camille FAUDEUX, Dr
Organizational Affiliation
Centre Hospitalier Universitaire de Nice
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU de Nice
City
Nice
ZIP/Postal Code
06001
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Camille FAUDEUX, Dr
Phone
04.92.03.63.65
Ext
+33
Email
faudeux.c@chu-nice.fr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Screening for Renal Complications in Children and Young Adults With Major Sickle Cell Disease

We'll reach out to this number within 24 hrs